The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Safety and PK/PD of ALLO-647 for lymphodepletion for allogeneic CAR-T
Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO, discuss a safety and pharmacodynamics (PD)/pharmacokinetics (PK) study of ALLO-647, an anti-CD52 antibody, with fludarabine (FLU)/cyclophosphamide (CY) for lymphodepletion in the setting of allogeneic CAR T-cell therapy. ALPHA (NCT03939026) and UNIVERSAL (NCT04093596) are ongoing trials in hematological malignancies assessing ALLO-501 and ALLO-715 allogeneic CAR T-cell therapy, respectively. ALLO-647 was used in both studies for lymphodepletion. Findings from the 72 patients treated as of the data cut-off demonstrated that ALL0-647 with FLU plus CY had a tolerable safety profile and produced a deep and durable window of lymphocyte depletion. Higher doses were associated with greater incidence and severity of infusion-related reactions, but also higher IL-15 levels and better CAR-T expansion, suggesting dose responses. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
